bioMerieux SA - Company Profile
Powered by 
All the data and insights you need on bioMerieux SA in one report.
$295
- Save hours of research time and resources with
our up-to-date bioMerieux SA Strategy Report
- Understand bioMerieux SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
bioMerieux SA (bioMerieux) is a global provider of clinical applications that facilitate improved industrial microbiological control and minimize the risks of contamination of pharmaceuticals, cosmetics, and food products throughout the production value chain.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
bioMerieux focuses on the development of platforms and enhancement of existing ones in the fields of infectious diseases, oncology and certain cardiovascular diseases, food and biopharmaceutical, and veterinary industries; and increase laboratory efficiency and medical value of diagnostic tests. The company has partnerships with public research institutes, universities, hospital research centers, laboratories and biotechnology firms for the development of new technologies. In FY2022, bioMerieux spent EUR446.6 million on its R&D activities, which as a percentage of revenue, stood at 12.4%. As of December 31, 2022, bioMerieux had 14 R&D centers worldwide and staffed 1,500 dedicated employees. It has R&D facilities in the US, France, Italy, Brazil, China, India, Germany and Belgium. In 2021, the company’s patent portfolio comprised 546 patent families in Europe, China, and the US, out of which 511 patents were granted in the US, and 246 in Europe; and it filed for 20 new patents.
Business Segments
Overview
Provides diagnostic tests for the detection of various infectious diseases including sepsis, respiratory infections, gastrointestinal infections, meningitis and encephalitis, AIDS and hepatitis; antimicrobial resistance and healthcare-associated infections; and acute coronary syndrome, pulmonary embolism and deep vein thrombosis, and acute heart failure. The company also offers companion, and complementary and supportive tests in the areas of personalized medicine through partnership with various pharmaceutical, vaccine and medical device companies. Major Microbiology products include automated microbial detection system, automated instruments for blood culture and ID/AST testing, mass spectrometry microbial identification system, test strip for MIC determination of ceftolozane/avibactam, culture media for detection of fungal infections, chromogenic media for urinary pathogen and pseudomonas aeruginosa, antimicrobial resistance management solutions and emergency diagnostic patient management solutions. Major Molecular Biology tests products include ARGENE Solution, a molecular biology solution for the monitoring of transplant patients, PCR kits, FILMARRAY multiplex PCR system, tests for respiratory viruses and bacteria, pathogens and antibiotic resistance genes associated with bloodstream infections, gastrointestinal pathogens, and meningitis encephalitis-associated pathogens; and BIOMERIEUX EPISEQ, genome sequencing for the epidemiological monitoring. Its molecular biology tests are used to detect pathogens, to identify antibiotic resistance mechanisms, measure the quantity of virus, monitor the effectiveness of treatment and determine the reaction of human cells to infection. Major Immunoassay tests include VIDAS immunoassay system test that is used in the diagnosis, screening and monitoring of diseases including viral infections, cardiovascular diseases, cancer and hormonal disorders; BIONEXIA, for the rapid detection of Legionella pneumophila, influenza A and B, streptococcus throat infections and gastritis; and VIKIA for the diagnosis of infectious diseases. Major laboratory efficiency products and services include automated microbiology specimen processing instrument, automated gram staining system, automated mycobacterial staining system, automated urinary screening system, lab organization services, quality management and training. Views partnerships and product innovation as critical factors for the growth of the division.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Develops and produces a range of industrial microbiological control solutions for the food, biopharmaceutical and cosmetics industries; veterinary diagnostic laboratories; and blood banks. Major products include solutions to detect pathogenic microorganisms including VIDAS, and culture media ranges such as CHROMID and GENE-UP molecular biology system; microorganism identification and strain typing products including API, VITEK 2 COMPACT; TEMPO and pre-poured media ranges; solutions to detect micro organisms in beverages such as CHEMUNEX and BACT/ALERT ranges; EVISIGHT compact total vision; endotoxin detection assays and services; culture media preparation and filling systems; environmental monitoring solutions; rapid microbial detection and sterility testing products; blood bank and cellular products; microbial identification solutions and non-sterile product testing products. Views launch of new products and increasing demand for molecular biology products as major contributors to growth.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer